Efficacy and adverse reactions of donepezil:a pharmacogenomic study
10.3969/j.issn.1009-0126.2024.02.013
- VernacularTitle:多奈哌齐疗效及不良反应相关的药物基因组学研究
- Author:
Hongmei SUN
1
;
Chao LÜ
;
Xuan SUN
;
Siyu CHEN
;
Xiaoxue ZHANG
;
Yuxin FENG
;
Tong YIN
;
Jianjun JIA
Author Information
1. 100853 北京,解放军总医院第二医学中心老年医学研究所国家老年疾病临床研究中心
- Keywords:
Alzheimer disease;
donepezil;
pharmacogenomic variants
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2024;26(2):171-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and adverse reactions of donepezil in the treatment of patients with a continuous disease spectrum of Alzheimer's disease(AD)with pharmacogenomics.Methods Seventy-two patients who took donepezil therapy at the time of initial molecular pa-thology diagnosis of AD continuous disease spectrum in Chinese PLA General Hospital from Jan-uary 2022 to January 2023 were recruited.Cells from the oral buccal mucosa were collected,and MassARRAY nucleic acid mass spectrometry was applied to detect the genotypes of CYP2D6,the gene encoding cytochrome P450 2D6 enzyme,and CHAT,the gene encoding acetylcholine trans-ferase.After 9 months of follow-up,drug efficacy was indirectly determined by neurological func-tion scales,caregiver evaluations,and drug prescribing behaviors,and thus,the 50 patients on donepezil alone were divide into effective group(n=28)and ineffective group(n=22).Seventy-two patients were divided into adverse reaction group(n=12)and no adverse reaction group(n=60).Multivariate logistic regression analysis was used to analyze the correlation between donepezil efficacy and pharmacogenomics.Results The frequencies of CHAT rs3793790 locus carrying G allele and rs2177370 locus carrying A allele were significantly higher in the effective group than the ineffective group(35.71％vs 9.09％,P=0.029;42.86％vs 9.09％,P=0.008).Multivariate lo-gistic regression analysis showed that donepezil was more effective in those who carrying rs3793790 G allele and/or rs2177370 A allele in the CHAT gene than those who carrying neither of the alleles(95％CI:1.20-34.47,P=0.030).There were no statistical differences in the CYP2D6 gene-adjusted activity score and whether or not carrying*10 between the patients with and without adverse reactions(P＞0.0 5).Conclusion In patients with a continuous spectrum of AD,donepezil efficacy is associated with CHAT gene polymorphisms,but there is no correlation between donepezil adverse reactions and CYP2D6 genotype.
